New Jersey touts biotech growth

A new survey of New Jersey's biotech industry has found that the drug development business is growing steadily. Combined public and private biotech revenue was set at $5 billion from 238 biotech companies in the state--up from 226 in 2006. And 86 percent of the surveyed companies said they expect to hire 20 or more employees in the next 12 months. Report

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.